↓ Skip to main content

The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Overview of attention for article published in BMC Musculoskeletal Disorders, August 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study
Published in
BMC Musculoskeletal Disorders, August 2016
DOI 10.1186/s12891-016-1213-6
Pubmed ID
Authors

Anna O’Connor, Carter Thorne, Hyeon Kang, Diane Tin, Janet E. Pope

Abstract

Methotrexate (MTX) is standard treatment for RA. Absorption is better in subcutaneous MTX (scMTX), which may impact speed of onset. In RA, earlier time to remission improves long-term results. Our objectives were to determine rapidity of response of subcutaneous methotrexate in early rheumatoid arthritis. The change in several disease activity measures (including DAS28) from 0 to 6 weeks (early period) and 6 to 12 weeks (late period) was compared. The proportion achieving DAS28/CDAI/SDAI remission and/or low disease activity state was also compared. One hundred three patients were included from a single site between 2008 and 2014. All received MTX (98.0 % scMTX, 98 % 25 mg/week). There were no dropouts. There was a significantly greater early change in DAS28 (-1.9 vs. -0.2, p < 0.00); this effect was seen for several outcome measures. By 6 weeks, 59 % had achieved either DAS28 remission or low disease activity state, with 74 % achieving either state by 12 weeks. There were a larger proportion of patients achieving CDAI and DAS28 remission in the early versus late period (p < 0.0002 for both). There was significant improvement when using combination MTX and HCQ, however sample size was small (n = 9). The use of intra-articular steroids with MTX yielded the most disease measures that demonstrated early significant improvement. Subcutaneous MTX is rapid, as the change in many disease activity scores was significantly greater between 0-6 weeks compared to 6-12 weeks. Combination MTX + HCQ gave added value, although generalizability is limited by combination cohort sample size. Intra-articular steroid injections may contribute to the early effect.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 5%
Canada 1 5%
Unknown 20 91%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 18%
Other 3 14%
Student > Master 3 14%
Researcher 3 14%
Student > Bachelor 2 9%
Other 2 9%
Unknown 5 23%
Readers by discipline Count As %
Medicine and Dentistry 9 41%
Biochemistry, Genetics and Molecular Biology 3 14%
Arts and Humanities 2 9%
Nursing and Health Professions 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Other 2 9%
Unknown 4 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2019.
All research outputs
#4,628,353
of 14,916,807 outputs
Outputs from BMC Musculoskeletal Disorders
#1,046
of 2,922 outputs
Outputs of similar age
#97,718
of 270,156 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#1
of 1 outputs
Altmetric has tracked 14,916,807 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,922 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,156 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them